Media ReleasesNext Science

View All Next Science News

Next Science - Managing Director's Address - Half Year Results

As you know, Next Science is a company whose purpose is to improve people’s health by eliminating or preventing infections. Through our unique technologies we have helped tens of thousands of people resume normal life and as we increase our focus on infection prevention, we look forward to the opportunity of quietly protecting millions of people from the complications of post operative infection.

Moving to slide 3. In this report, I’ll focus on our platform technology and products, the execution milestones we have achieved in the last half and the progress we are making in attaining VAC approvals to commercialise XPerience – our market leading No Rinse Antimicrobial Solution that has been launched in the United States. I will explain the VAC process later in the presentation. 

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.